<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369950</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-19-0951</org_study_id>
    <nct_id>NCT04369950</nct_id>
  </id_info>
  <brief_title>Post-cesarean Analgesia With Epidural Morphine Following Epidural 2-chloroprocaine</brief_title>
  <official_title>Post-cesarean Analgesia With Epidural Morphine Following Epidural 2-chloroprocaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show that the effect of 3% 2-chloroprocaine prior to epidural
      morphine administration will be not inferior to the effect of epidural 2% lidocaine with
      1:200,000 epinephrine on total opioid use for 24h
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 11, 2020</start_date>
  <completion_date type="Anticipated">July 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total amount of opioid used</measure>
    <time_frame>4 hours after epidural morphine administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>total amount of opioid used</measure>
    <time_frame>8 hours after epidural morphine administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>total amount of opioid used</measure>
    <time_frame>12 hours after epidural morphine administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>total amount of opioid used</measure>
    <time_frame>24 hours after epidural morphine administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>total amount of opioid used</measure>
    <time_frame>36 hours after epidural morphine administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain as measured by a 11 point verbal scale</measure>
    <time_frame>every 4 hours for the first 12 hours,every 12 hours for the next 24 hours</time_frame>
    <description>scale ranges form 0-10,higher number indicating more pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea as measured by a 3 point scale</measure>
    <time_frame>every 4 hours for the first 12 hours,every 12 hours for the next 24 hours</time_frame>
    <description>scale ranges from non,mild and moderate-severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritis as measured by a 3 point scale</measure>
    <time_frame>every 4 hours for the first 12 hours,every 12 hours for the next 24 hours</time_frame>
    <description>scale ranges from non,mild and moderate-severe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Physiological Effect of Drugs</condition>
  <condition>Morphine</condition>
  <condition>Analgesics</condition>
  <condition>Analgesics, Opioid</condition>
  <condition>Central Nervous System Depressants</condition>
  <condition>Narcotics</condition>
  <arm_group>
    <arm_group_label>2 percent Lidocaine with epinephrine and epidural morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 percent 2-Chloroprocaine and epidural morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% lidocaine with 1:200,000 epinephrine and epidural morphine</intervention_name>
    <description>Epidurals will be dosed with 2% lidocaine with 1:200,000 epinephrine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.</description>
    <arm_group_label>2 percent Lidocaine with epinephrine and epidural morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% 2-chloroprocaine and epidural morphine</intervention_name>
    <description>Epidurals will be dosed with 3% 2-chloroprocaine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. This is the critical component to bridge the latency period between the offset of 3% 2-chloroprocaine and the peak action of epidural morphine.Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.</description>
    <arm_group_label>3 percent 2-Chloroprocaine and epidural morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant patients

          -  live singleton pregnancy

        Exclusion Criteria:

          -  BMI &gt;40

          -  obstructive sleep apnea

          -  drug abuse

          -  chronic pain

          -  chronic opioid use

          -  nonfunctioning epidural
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linden Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linden Lee, MD</last_name>
    <phone>(713) 500-6200</phone>
    <email>Linden.O.Lee@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Lisa Ramirez-Chapman, MD</last_name>
    <phone>(713) 566-5971</phone>
    <email>Ana.L.RamirezChapman@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Linden Lee, MD</last_name>
      <phone>713-500-6200</phone>
      <email>Linden.O.Lee@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ana Lisa Ramirez-Chapman, MD</last_name>
      <phone>(713) 566-5971</phone>
      <email>Ana.L.RamirezChapman@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>May 2, 2020</last_update_submitted>
  <last_update_submitted_qc>May 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Linden Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>cesarean delivery</keyword>
  <keyword>c-section</keyword>
  <keyword>chloroprocaine</keyword>
  <keyword>lidocaine</keyword>
  <keyword>morphine</keyword>
  <keyword>post-operative pain</keyword>
  <keyword>post-cesarean analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Chloroprocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

